explore -WSS

explore

author：hotspot 2025-09-30 11:07:21 - browse：43

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Senators start work on Medicare physician payment reform

Wikipedia

WSS

What should King Charles tell the public about his cancer?

Readout LOUD podcast: How biotech is using artificial intelligence

Why the quest to eradicate polio has stumbled

Patients, doctors press FTC to beef up hospital merger scrutiny

Biogen Alzheimer’s drug launch off to slow start

People with substance use disorder deserve online privacy

hotspot

explore

knowledge

At least 13 dead in Texas as scorching temps continue

Akili changes sales model for its ADHD video game treatment

As demand for Covid shots wanes, Moderna seeks its next success

Why the quest to eradicate polio has stumbled

Medical leaders decry Supreme Court decision on affirmative action

Senators start work on Medicare physician payment reform

In age of alternative facts, a scholarly course on calling out crap

Assistant physicians can help address the primary care shortage

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why did Pfizer dish out millions for a Super Bowl ad?

leisure time

What happened to the House vote on health price transparency?

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

What we’ve learned from the Aduhelm mess

Chamber of Commerce, DOJ clash in court over drug prices

PhRMA lawsuit over Medicare drug price negotiation tossed

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

hotspot

focus

Wikipedia

focus